Nurix Therapeutics, Inc. 该公司是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为癌症和免疫紊乱的新治疗方法。利用他们在E3连接酶方面的广泛专业知识以及他们的专有DNA编码库，该公司已经建立了一个集成的发现平台 DELigase，以识别和开发针对E3连接酶的新药物候选。于2009年8月27日在特拉华州成立。
中文介绍: https://xueqiu.com/S/NRIX
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
英文介绍: https://www.morningstar.com/stocks/xnas/nrix/quote
主题测试文章，只做测试使用。发布者：star，转转请注明出处：https://wallstreetgm.com/nrix-nurix-therapeutics-inc/
